Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies.
COVID-19
Hematological malignancies
Immunocompromised
T cell responses
Third dose
Vaccine
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
24 02 2023
24 02 2023
Historique:
received:
21
05
2022
revised:
28
11
2022
accepted:
25
01
2023
pubmed:
4
2
2023
medline:
3
3
2023
entrez:
3
2
2023
Statut:
ppublish
Résumé
Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies with cytotoxic chemotherapies that could result in an even greater alteration of the immune response to vaccination. We report here the impact of a third vaccine dose on T cell specific responses in a small cohort of patients treated in our center by anti-CD20 therapies and cytotoxic chemotherapies for lymphoid malignancies. Our results showed that a third dose in these severely immune suppressed patients could improve the expansion on CD4
Identifiants
pubmed: 36737320
pii: S0264-410X(23)00095-6
doi: 10.1016/j.vaccine.2023.01.064
pmc: PMC9884622
pii:
doi:
Substances chimiques
BNT162 Vaccine
0
Vaccines, Synthetic
0
Antibodies
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1550-1553Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: F. Lemonnier received research funding from Institut Roche and travel grant from Gilead, G. Melica received non-financial support from MSD and research grants and non-financial support from Pfizer.
Références
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Haematologica. 2022 Mar 01;107(3):755-758
pubmed: 34854280
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959
Nat Commun. 2020 Jul 24;11(1):3730
pubmed: 32709840
Cancer Cell. 2021 Aug 9;39(8):1034-1036
pubmed: 34348121
Cancer Cell. 2021 Oct 11;39(10):1297-1299
pubmed: 34509182
Am J Hematol. 2021 Aug 1;96(8):934-944
pubmed: 33909916
Blood. 2022 Jul 14;140(2):156-160
pubmed: 35472242
Blood. 2022 Jan 6;139(1):142-147
pubmed: 34669919
Clin Microbiol Infect. 2022 Jun;28(6):885.e7-885.e11
pubmed: 35259530
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
Lancet Rheumatol. 2022 Jan;4(1):e13-e16
pubmed: 34778844
Cancer Cell. 2021 Aug 9;39(8):1031-1033
pubmed: 34331856
Blood. 2022 Jul 14;140(2):152-156
pubmed: 35537186
Lancet Haematol. 2021 Aug;8(8):e583-e592
pubmed: 34224668